Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Ocugen, Inc.
  • About
    +
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Founders
  • Vaccine
    +
    • Vaccine Overview
    • Scientific Advisory Board
    • Publications
  • Pipeline
    +
    • Pipeline Overview
    • Modifier Gene Therapy Platform
    • OCU400
    • OCU410
    • OCU200
    • COVAXIN™
  • News
    +
    • News
    • Events
    • Press Releases
  • Investors
    +
    • Investor Overview
    • Stock Information
      +
      • Historic Price Lookup
      • Investor Calculator
      • Analyst Coverage
    • Financial Information
      +
      • SEC Filings
      • Financial Reports
      • Quarterly Reports
    • Presentations
    • Corporate Governance
    • Investor Resources
      +
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact
Contact

News & Events

Beyond Luxturna companies vie to become the next ocular gene therapy

February 22, 2021

Ocugen Inc. is tackling retinitis pigmentosa (RP), which is caused by mutations in well over 100 mutations.

Read More

Ocugen finalizes deal to co-develop Covid-19 vaccine

February 3, 2021 Philadelphia Business Journal

Chester County biopharmaceutical company Ocugen has finalized an agreement with Bharat Biotech of India to co-develop Bharat’s Covid-19 vaccine for the United States market.

Read More

Inside the Covid-19 vaccine deal that boosted Ocugen’s stock price by 800%

January 7, 2021 Philadelphia Business Journal

While Ocugen has focused on developing gene therapy treatments for retinal diseases since its inception in 2013, the Malvern biopharmaceutical company expanded into a new arena two weeks ago. On Dec. 22, Ocugen announced it signed a binding letter of intent with Bharat Biotech of India to co-develop Bharat’s Covid-19 vaccine candidate for the United States market.

Read More

How Bharat Biotech’s Vaccine Works

January 4, 2021 New York Times

The Indian company Bharat Biotech partnered with the National Institute of Virology and the Indian Council of Medical Research to develop an inactivated coronavirus vaccine called Covaxin.

Read More

Timeline: India’s coronavirus vaccine approved by drugs experts

January 2, 2021 Reuters

India’s drugs regulator on Saturday recommended for emergency use a locally developed coronavirus vaccine called COVAXIN, which is expected to be a backup to the AstraZeneca/Oxford shot. COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Research (ICMR).

Read More

Commanders & Chiefs: Biopharma Chief Executive Officers

January 1, 2021 Pharmavoice

CEOs of biopharma organizations face unprecedented challenges as they lead their companies amid a global pandemic, shoring up their organizations during turmoil, and learning valuable lessons along the way.

Read More

Indian Companies Find US Partners For COVID-19 Vaccines

December 24, 2020 Scrip

Serum Institute has struck a partnership with Dynavax and Aurobindo Pharma with US-based company COVAXX for new vaccine candidates while Bharat Biotech has tied up with Ocugen to explore marketing of its existing contender, Covaxin, in the US.

Read More

6 Biopharma CFOs Discuss The Pandemic’s Impact On The Supply Chain, Their Job And More

December 10, 2020 Life Science Leader

The first year Life Science Leader began involving finance executives in our annual outlook issue (2018) we had just one biopharmaceutical company CFO participate. This year we had eight.

Read More

Ocugen Selected as a Finalist for the Buzz of BIO Contest, recognizing some of the most innovative companies at the 2021 CEO & Investor Digital Conference.

December 9, 2020

Please vote for us in the Public Therapeutic Biotech category! Check out the top 3 reasons to vote for us and cast your vote here: https://bit.ly/CEObuzz21. Voting begins at 9 a.m. on Wednesday, December 9 and runs through 5 p.m. on Friday, December 11.

Read More

How Will The Pandemic Impact Biopharma’s Annual Kickoff?

December 9, 2020 Life Science Leader

When I emailed questions to this year’s annual outlook finance article participants in early September, it still wasn’t clear if biopharma’s annual kickoff meeting (i.e., JPM in San Francisco in early January) would be in-person or virtual.

Read More

What Do Biopharma CFOs Think About The Market’s Future?

December 4, 2020 Life Science Leader

To say the biopharmaceutical stock market has never been hotter would not be an “unprecedented” overstatement. As of late August, there have been more IPOs than in all of 2019.

Read More

SPECIAL REPORT: Xcelerating Life Sciences New York & Philadelphia

December 3, 2020 Turtl

For Ocugen CEO Shankar Musunuri, high pricing remains the biggest hurdle to securing reimbursement for cell and gene therapies.

Read More

What Do 10 Biopharma Finance Experts Expect for 2021

December 2, 2020 Life Science Leader

CFO Sanjay Subramanian Contributes to Life Science Leader article on “What Do 10 Biopharma Finance Experts Expect for 2021.”

Read More

Ocugen Signs Deal with Indian CMO to Avoid US Capacity Constraints

October 12, 2020 BioProcess International

Ocugen has signed a manufacturing deal with Kemwell Biopharma for a potential treatment of retinal diseases.

Read More

Gene Therapy’s Renaissance

October 2, 2020 Genetic Engineering News

Ophthalmologist Mohamed Genead, MD, chair of Ocugen’s retina scientific advisory board, is excited about a revolutionary new approach—the modifier gene platform—that takes a “gene-independent approach” by overexpressing upstream regulatory genes for nuclear hormone receptors (NHRs) in retinal cells instead of attempting to correct mutations in individual genes.

Read More

Ocugen Eyes Broad Retinitis Pigmentosa Indication with One Gene Therapy

August 28, 2020 Scrip

Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.

Read More

Malvern Gene Therapy Company Nabs Fourth Orphan Drug Designation for a Single Product

August 14, 2020 Philadelphia Business Journal

A Chester County gene therapy company specializing in eye diseases has received its fourth "orphan drug" designation for a single new drug candidate from the Food and Drug Administration.

Read More

More Than Meets the Eye: Challenges in Developing Gene Therapies for Rare Eye Diseases

June 2, 2020

An overwhelming majority of rare diseases are the result of a single-gene defect, making them a potential target in the hunt for treatment.

Read More

Ocugen, Inc. | CEORoadshow

April 24, 2020 CEORoadshow

CEORoadshow interviewed Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-Founder of Ocugen, Inc., in April 2020. 

Read More

Gene Therapy Innovation and Product Development

April 24, 2020

Disrupting the current norms of the drug development process has always been the cornerstone of biopharmaceutical innovation.

Read More

A One-to-Many Approach to Gene Therapy for Retinal Disease

April 10, 2020

We spoke to Shankar Musunuri, CEO of Ocugen, about the company’s modifier gene therapy platform, how a single gene therapy can work on multiple eye diseases, and how it may alter the economics for gene therapy for rare eye conditions.

Read More

Working toward a broad-spectrum therapy

April 3, 2020 DDNews

Clinical-stage company Ocugen Inc. shared last month that preclinical data regarding the nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat retinal degenerative diseases had been published in Nature Gene Therapy.

Read More

Promising Early Findings on First-of-its-Kind Retinitis Pigmentosa Therapy

March 5, 2020 Mass. Eye and Ear Communications

Retinitis pigmentosa is a group of blinding eye diseases caused by more than 150 different gene mutations, making effective therapies difficult to develop. A new treatment created by scientists at Massachusetts Eye and Ear aims to provide broad-spectrum therapy, regardless of genetic cause, with promising early results in animals.

Read More

BioTuesday: Ocugen developing therapies for rare and underserved eye diseases

February 25, 2020 BioTuesday

Ocugen developing therapies for rare and underserved eye diseases

Read More

NextUp: This Company Is Using Gene Therapy to Target Rare Eye Diseases

February 10, 2020 Philadelphia Magazine

Ocugen has developed a new platform that could help bring greater attention to underserved areas of ophthalmology.

Read More

Ocugen Sets Sights on First Ocular GVHD Treatment

February 3, 2020 Xtalks

Xtalks spoke with Ocugen's Shankar Musunuri to learn more about a novel drug delivery system and drug candidate pairing for the treatment of ocular Graft versus Host Disease (GVHD).

Read More

Ocugen looking to lead the way with their new gene therapy platform

January 6, 2020 Proactive

Ocugen Inc (NASDAQ: OCGN) CEO Shankar Musunuri spoke with Steve Darling from Proactive at the LD Micro Conference in Bel Air, California. The Pennsylvania-based clinical-stage biopharmaceutical company is focused on developing therapies to treat rare and underserved eye diseases.

Read More

Developing Innovative Therapies to Treat Rare and Underserved Eye Diseases

November 27, 2019 Pharma's Almanac

Ocugen offers a robust and diversified ophthalmology portfolio that includes novel gene therapies, biologics and small molecules targeting a range of high-need retinal and ocular surface diseases.

Read More

Ocugen wins orphan drug status for ocular gene therapy

February 14, 2019 Drug Delivery Business News

The FDA has given Ocugen orphan drug status for a gene therapy designed to treat NR2E3 mutation-associated retinal degenerative disease.

Read More

Ocugen, Inc. and its Mission to Develop Innovative Therapies to Address Underserved Eye Diseases

January 9, 2019 Health Professional Radio

Dr. Shankar Musunuri, Ph.D., MBA, is Chairman of the Board, CEO and Co-founder of Ocugen, Inc., discusses the Company’s lead clinical candidate (OCU300) that is currently in Phase 3 for patients with ocular graft versus host disease (oGVHD) and is the first and only therapeutic with orphan drug designation for oGVHD, and the Company’s second lead candidate (OCU310) which is also in Phase 3 for patients with dry eye disease.

Read More

Ocugen kicks off dry eye disease trial for nanoemulsion eye drop

October 7, 2018 Drug Delivery Business News

Ocugen said today that it launched a Phase III trial designed to evaluate its twice-daily 0.2% brimonidine tartrate eye drop in patients with dry eye disease.

Read More

‘Finding regimens that work’ | No ‘DED’ zone in dry eye as midstage pipeline perks up

August 6, 2018 BioWorld

To the layperson, dry eye disease (DED), technically xerophthalmia, often is dismissed as an innocuous nuisance that can be treated with over-the-counter eye drops.

Read More

Ocugen launches Ph3 trial for eye disease nanoemulsion

July 2, 2018 Drug Delivery Business News

Ocugen said today that it launched the first of two pivotal Phase III trials for its OCU300 nanoemulsion designed to treat the symptoms of ocular graft versus host disease.

Read More

Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs

March 20, 2018 Scrip

Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved
ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.

Read More

Ocugen preps dry eye disease drug for phase 3

March 20, 2018 FierceBiotech

Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial.

Read More

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

January 15, 2018 Scrip

While Allergan PLC and Shire PLC are jockeying for supremacy in the dry eye disease space, with the former's Restasis (cyclosporine ophthalmic emulsion) losing market share to the latter's Xiidra (lifitegrast), a host of other companies have candidates in clinical development for dry eye addressing a wide variety of targets in the hopes of bettering the existing therapies or benefiting an underserved niche.

Read More

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 Drug Delivery Business News

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out.

Read More

Ocugen CEO Dr. Shankar Musunuri Named a 2017 ‘Most Admired CEO’ by the Philadelphia Business Journal

December 8, 2017

Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies and novel biologics that address rare and underserved ocular diseases, today announced its Co-Founder, Chairman and Chief Executive Officer Shankar Musunuri, Ph.D., MBA, was named one of the “Most Admired CEO’s in 2017” by the Philadelphia Business Journal.

Read More

Ocugen, Inc.

Ocugen, Inc.

  • 263 Great Valley Parkway
    Malvern, PA 19355
  • 484.328.4701

Quick Links

  • About
  • News
  • Events
  • Press
  • Pipeline
  • Investors
  • Careers
  • Contact

Keep In Touch


© 2021 Ocugen, Inc. All Rights Reserved.